Pharming Group NV
Research Pharming Group NV (PHARM) on Bullrun: market cap EUR 709.55M, P/E 100.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHARM
- ExchangeAS
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 709.55M
- P/E100.3
- Financial periodQ2 2026
- RevenueUSD 90.21M
- Net incomeUSD 1.64M
- Free cash flow-USD 9.74M
- Gross margin83.9%
Valuation Snapshot
latest market cap is EUR 709.55M; P/E is 100.3.
Peer valuation comparison
Latest P/E is 100.25x versus a Healthcare sector median of 24.46x (309.9% above).
Latest P/E is 100.25x versus a Netherlands median of 18.23x (449.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 376.13M | USD 2.54M | USD 53.96M | 87.9% | 0 | USD 145.31M | USD 115.78M | USD 277.10M |
| FY2024 | USD 297.20M | -USD 11.84M | -USD 2.59M | 88.1% | -0.02 | USD 54.94M | USD 112.31M | USD 221.06M |
| FY2023 | USD 245.32M | -USD 10.55M | -USD 18.74M | 89.7% | -0.02 | USD 61.74M | n/a | USD 218.78M |
| FY2022 | USD 205.62M | USD 13.67M | USD 21.08M | 91.5% | 0.02 | USD 207.34M | n/a | USD 204.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 709.55M | 100.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharming Group NV's market cap?
Pharming Group NV's market capitalization is EUR 709.55M.
What is Pharming Group NV's P/E ratio?
Pharming Group NV's price-to-earnings (P/E) ratio is 100.3.
What does Pharming Group NV do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K?